Sensible Biotechnologies
Cambridge
About Sensible Biotechnologies
Sensible Biotechnologies is developing world's first cell-based platform to unlock the next generation of mRNA medicines.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $10.4M
- Funding stage: Seed
- Last round: Grant (Sep 2025)
- Website: sensible.bio
- Phone: [email protected]
Industries & Categories
Biotechnology, Medical
Social Profiles
Canonical: https://fsome.com/organization/sensible-biotechnologies-3933 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.